- Home
- Severe Hypertriglyceridaemia: Defining the Disease and Its Management
Severe Hypertriglyceridaemia: Defining the Disease and Its Management
- CV Renal Metabolic
- Prevention
Available Credit:
- 1.00
Course Published On:
Course Expiry Date:
Overview
Part of New Horizons in Dyslipidaemia (NHD) 2026, this expert-led symposium explores the rapidly evolving landscape of hypertriglyceridaemia (HTG) and the increasingly central role cardiologists play in its identification, risk stratification, and management.
As our understanding of triglyceride-rich lipoproteins deepens, so too does recognition of their contribution to residual cardiovascular risk and acute pancreatitis. This session brings together leading experts to examine HTG across the clinical spectrum—from common mixed dyslipidaemia to rare genetic disorders while highlighting emerging therapeutic targets and practical management strategies for cardiovascular specialists.
Support Statement
This symposium is supported by an unrestricted educational grant from Arrowhead Pharmaceuticals.
Disclosure
In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
The session, ‘Severe Hypertriglyceridaemia: Defining the Disease and Its Management’ is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
Instruction to Participants
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Target Audience
Target Audience
- General Cardiologists
- Interventional Cardiologists
- Lipid Specialists
- Primary Care
- Endocrinologists
Learning Objectives
- Recall the mechanisms that make TGs a risk factor for atherosclerosis
- Review how elevated FCS is a major risk factor for pancreatitis
- Discuss the current clinical evidence of TG-lowering therapies in different disease states
Module |
Title |
Duration |
Speakers |
|---|---|---|---|
| Part 1 | Hypertriglyceridaemia: From Mixed Hyperlipidaemia to FCS | 12m | Erin D Michos (Baltimore, US) |
| Part 2 | ApoC-III:An Emerging Target in HTG | 23m | Ioanna Gouni-Berthold (Cologne, DE) |
| Part 3 | Management in Cardiology | 14m | Lale Tokgözoğlu (Ankara, TR) |
| Part 4 | Panel Discussion and Audience Q&A | 3m | Ioanna Gouni-Berthold (Cologne, DE) Daniel Gaudet (Montreal, CA) Erin D Michos (Baltimore, US) Lale Tokgözoğlu (Ankara, TR) |
Hypertriglyceridaemia: From Mixed Hyperlipidaemia to FCS
Duration: 12m
Speakers: Erin D Michos (Baltimore, US)
Panel Discussion and Audience Q&A
Duration: 3m
Speakers: Ioanna Gouni-Berthold (Cologne, DE) Daniel Gaudet (Montreal, CA) Erin D Michos (Baltimore, US) Lale Tokgözoğlu (Ankara, TR)
Chair
Speaker